See more : ATI Airtest Technologies Inc. (AAT.V) Income Statement Analysis – Financial Results
Complete financial analysis of Verastem, Inc. (VSTM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Verastem, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Provexis plc (PXS.L) Income Statement Analysis – Financial Results
- DB Financial Investment Co., Ltd. (016610.KS) Income Statement Analysis – Financial Results
- Golden Apple Oil & Gas Inc. (GAPJ) Income Statement Analysis – Financial Results
- KOA Corporation (6999.T) Income Statement Analysis – Financial Results
- Paref SA (PAR.PA) Income Statement Analysis – Financial Results
Verastem, Inc. (VSTM)
About Verastem, Inc.
Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylate MEK. The company also engages in developing RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of VS-6766 and in combination with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK) in patients with recurrent low grade serous ovarian cancer; and RAMP 202, which is in Phase 2 trial to evaluate the safety of VS-6766 in combination with defactinib in patients with KRAS and BRAF mutant non-small cell lung cancer following treatment with a platinum-based regimen and immune checkpoint inhibitor. Verastem, Inc. has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing VS-6766; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic and prophylactic uses in humans. In addition, it has clinical collaboration agreement with Amgen, Inc. to evaluate the combination of VS-6766 with Amgen's KRAS-G12C inhibitor LUMAKRASTM which in Phase 1/2 trial entitled RAMP 203. The company was incorporated in 2010 and is headquartered in Needham, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 2.60M | 2.05M | 88.52M | 17.46M | 26.72M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 62.00K | 118.00K | 206.00K | 33.75M | 2.81M | 165.00K | 556.00K | 670.00K | 754.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -62.00K | 2.48M | 1.85M | 54.77M | 14.65M | 26.55M | -556.00K | -670.00K | -754.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 95.45% | 89.97% | 61.88% | 83.92% | 99.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 61.36M | 50.56M | 39.35M | 41.38M | 45.78M | 43.65M | 46.42M | 19.78M | 40.57M | 35.45M | 25.93M | 21.71M | 9.88M | 400.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 77.27M | 21.38M | 17.22M | 17.63M | 18.16M | 15.47M | 10.52M | 3.82M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.67M | 24.98M | 24.12M | 62.76M | 101.21M | 77.27M | 21.38M | 17.22M | 17.63M | 18.16M | 15.47M | 10.52M | 3.82M | 576.00K |
| Other Expenses | 0.00 | 47.00K | 0.00 | -1.31M | -641.00K | 423.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -288.00K |
| Operating Expenses | 92.08M | 75.53M | 63.46M | 104.13M | 146.99M | 121.34M | 67.80M | 37.00M | 58.20M | 53.61M | 41.40M | 32.23M | 13.70M | 688.00K |
| Cost & Expenses | 92.08M | 75.53M | 63.46M | 137.88M | 149.80M | 121.50M | 67.80M | 37.00M | 58.20M | 53.61M | 41.40M | 32.23M | 13.70M | 688.00K |
| Interest Income | 6.21M | 1.22M | 181.00K | 515.00K | 4.38M | 2.60M | 561.00K | 562.00K | 334.00K | 242.00K | 200.00K | 246.00K | 15.00K | 0.00 |
| Interest Expense | 4.14M | 2.14M | 9.97M | 15.79M | 20.61M | 5.81M | 559.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 62.00K | 118.00K | 206.00K | 1.32M | 2.00M | 1.42M | 556.00K | 670.00K | 754.00K | 427.00K | 236.00K | 207.00K | 83.00K | 0.00 |
| EBITDA | -83.17M | -71.56M | -61.02M | -50.41M | -126.60M | -65.21M | -66.69M | -35.77M | -57.11M | -52.94M | -40.97M | -31.78M | -13.62M | -784.00K |
| EBITDA Ratio | 0.00% | -2,760.98% | -2,982.37% | -53.76% | -724.23% | -339.70% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -92.08M | -72.94M | -61.41M | -49.36M | -132.34M | -94.78M | -67.80M | -37.00M | -58.20M | -53.61M | -41.40M | -32.23M | -13.70M | -784.00K |
| Operating Income Ratio | 0.00% | -2,809.59% | -2,991.18% | -55.76% | -758.14% | -354.75% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.72M | -875.00K | -9.79M | -18.17M | -16.87M | 22.35M | 2.00K | 562.00K | 334.00K | 242.00K | 200.00K | 246.00K | 15.00K | 0.00 |
| Income Before Tax | -87.37M | -73.81M | -71.20M | -67.53M | -149.21M | -72.43M | -67.80M | -36.44M | -57.87M | -53.37M | -41.20M | -31.98M | -13.68M | -784.00K |
| Income Before Tax Ratio | 0.00% | -2,843.30% | -3,468.10% | -76.29% | -854.77% | -271.11% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 36.00K | 9.90M | 194.00K | 19.97M | 28.16M | 561.00K | 0.00 | -754.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -87.37M | -73.85M | -81.10M | -67.73M | -169.18M | -72.43M | -67.80M | -36.44M | -57.87M | -53.37M | -41.20M | -31.98M | -13.68M | -786.00K |
| Net Income Ratio | 0.00% | -2,844.68% | -3,950.32% | -76.51% | -969.16% | -271.11% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.96 | -4.58 | -5.58 | -5.30 | -27.22 | -12.54 | -21.18 | -11.82 | -19.32 | -24.82 | -21.80 | -20.45 | -8.11 | -0.53 |
| EPS Diluted | -3.96 | -4.58 | -5.58 | -5.30 | -27.22 | -12.54 | -21.18 | -11.82 | -19.32 | -24.82 | -21.80 | -20.45 | -8.11 | -0.53 |
| Weighted Avg Shares Out | 22.05M | 16.14M | 14.53M | 12.78M | 6.21M | 5.78M | 3.20M | 3.08M | 2.99M | 2.15M | 1.89M | 1.56M | 1.69M | 1.47M |
| Weighted Avg Shares Out (Dil) | 22.05M | 16.14M | 14.53M | 12.78M | 6.21M | 5.78M | 3.20M | 3.08M | 2.99M | 2.15M | 1.89M | 1.56M | 1.69M | 1.47M |
Verastem (VSTM) Up 8% on Fast Track Tag for NSCLC Combo Therapy
Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)
PRISM MarketView Announces the Addition of Verastem to Emerging Women's Health Index
Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem Oncology Selects Oral KRAS G12D Inhibitor GFH375/VS-7375 as Lead Program in Discovery and Development Collaboration with GenFleet Therapeutics
3 Off-the-Beaten-Path Stocks Poised for Substantial Growth
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
Small Stakes, Big Rewards: 3 Penny Stocks with 300% Upside Potential
3 Penny Stocks to Buy to Turn $1 into $100: November 2023
Source: https://incomestatements.info
Category: Stock Reports